Latterell Venture Partners

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company’s lead investigational therapy, NP001, targets chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson’s disease, and multiple sclerosis by regulating activated macrophages. Neuraltus has a robust pipeline that includes three clinical-stage programs aimed at addressing significant unmet medical needs, which also encompass dyskinesias associated with Parkinson's treatment and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents a unique approach with the potential to offer first-in-class treatment options for these challenging conditions, highlighting Neuraltus’s commitment to advancing healthcare solutions for patients suffering from neurodegenerative disorders.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

PerceptiMed, Inc. is a technology company based in Mountain View, California, specializing in medication verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. Founded in 2011, the company offers a range of products, including the IdentRx automated medication-verification device, which ensures accurate prescription pill verification and administration. Complementing this device is IdentRx Remote, software that facilitates remote verification of dispensed pills, and MedPass, a system aimed at preventing errors in pill administration. Additionally, PerceptiMed provides ScripClip, an electronic tagging system to enhance medication management. The company's innovative VeriFill technology ensures 100% verification of drug, dosage, and manufacturer for each pill dispensed, positioning PerceptiMed as a leader in the healthcare technology sector.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Transcend Medical, Inc. is an ophthalmic device company based in Menlo Park, California, focused on developing innovative medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005, Transcend Medical emerged from ForSight Labs, an incubator dedicated to ophthalmic innovations. The company's flagship product, the CyPass Micro-Stent, is a micro-invasive device designed to be implanted during routine cataract surgery to reduce intraocular pressure. Additionally, Transcend Medical offers the Vold Gonio Lens for use in micro-invasive glaucoma surgeries and provides clinical trial services. The CyPass Micro-Stent received its CE mark in 2008 and has been undergoing evaluation in various clinical studies, including the COMPASS multi-center trial, to assess its effectiveness and safety in treating glaucoma. As of 2016, Transcend Medical operates as a subsidiary of Alcon Holdings, Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company’s lead investigational therapy, NP001, targets chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson’s disease, and multiple sclerosis by regulating activated macrophages. Neuraltus has a robust pipeline that includes three clinical-stage programs aimed at addressing significant unmet medical needs, which also encompass dyskinesias associated with Parkinson's treatment and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents a unique approach with the potential to offer first-in-class treatment options for these challenging conditions, highlighting Neuraltus’s commitment to advancing healthcare solutions for patients suffering from neurodegenerative disorders.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company’s lead investigational therapy, NP001, targets chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson’s disease, and multiple sclerosis by regulating activated macrophages. Neuraltus has a robust pipeline that includes three clinical-stage programs aimed at addressing significant unmet medical needs, which also encompass dyskinesias associated with Parkinson's treatment and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents a unique approach with the potential to offer first-in-class treatment options for these challenging conditions, highlighting Neuraltus’s commitment to advancing healthcare solutions for patients suffering from neurodegenerative disorders.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Transcend Medical, Inc. is an ophthalmic device company based in Menlo Park, California, focused on developing innovative medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005, Transcend Medical emerged from ForSight Labs, an incubator dedicated to ophthalmic innovations. The company's flagship product, the CyPass Micro-Stent, is a micro-invasive device designed to be implanted during routine cataract surgery to reduce intraocular pressure. Additionally, Transcend Medical offers the Vold Gonio Lens for use in micro-invasive glaucoma surgeries and provides clinical trial services. The CyPass Micro-Stent received its CE mark in 2008 and has been undergoing evaluation in various clinical studies, including the COMPASS multi-center trial, to assess its effectiveness and safety in treating glaucoma. As of 2016, Transcend Medical operates as a subsidiary of Alcon Holdings, Inc.

Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas. Established in 2002, it specializes in creating innovative products for direct patient care, particularly focusing on oxygen delivery solutions for individuals with respiratory conditions. The company’s flagship products include the LifeChoice stationary and portable oxygen concentrators, which utilize a pulse mode system to provide varying levels of supplemental oxygen. Inova Labs also offers a range of accessories, such as carrying cases, external batteries, and power adapters. These products are distributed through authorized providers, primarily via their online platforms, ensuring accessibility for patients in need of oxygen therapy.

Transcend Medical, Inc. is an ophthalmic device company based in Menlo Park, California, focused on developing innovative medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005, Transcend Medical emerged from ForSight Labs, an incubator dedicated to ophthalmic innovations. The company's flagship product, the CyPass Micro-Stent, is a micro-invasive device designed to be implanted during routine cataract surgery to reduce intraocular pressure. Additionally, Transcend Medical offers the Vold Gonio Lens for use in micro-invasive glaucoma surgeries and provides clinical trial services. The CyPass Micro-Stent received its CE mark in 2008 and has been undergoing evaluation in various clinical studies, including the COMPASS multi-center trial, to assess its effectiveness and safety in treating glaucoma. As of 2016, Transcend Medical operates as a subsidiary of Alcon Holdings, Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.

Transcend Medical, Inc. is an ophthalmic device company based in Menlo Park, California, focused on developing innovative medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005, Transcend Medical emerged from ForSight Labs, an incubator dedicated to ophthalmic innovations. The company's flagship product, the CyPass Micro-Stent, is a micro-invasive device designed to be implanted during routine cataract surgery to reduce intraocular pressure. Additionally, Transcend Medical offers the Vold Gonio Lens for use in micro-invasive glaucoma surgeries and provides clinical trial services. The CyPass Micro-Stent received its CE mark in 2008 and has been undergoing evaluation in various clinical studies, including the COMPASS multi-center trial, to assess its effectiveness and safety in treating glaucoma. As of 2016, Transcend Medical operates as a subsidiary of Alcon Holdings, Inc.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company’s lead investigational therapy, NP001, targets chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson’s disease, and multiple sclerosis by regulating activated macrophages. Neuraltus has a robust pipeline that includes three clinical-stage programs aimed at addressing significant unmet medical needs, which also encompass dyskinesias associated with Parkinson's treatment and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents a unique approach with the potential to offer first-in-class treatment options for these challenging conditions, highlighting Neuraltus’s commitment to advancing healthcare solutions for patients suffering from neurodegenerative disorders.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on discovering and developing innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody designed to target Delta-like ligand 4 and vascular endothelial growth factor, which has undergone clinical trials for advanced solid tumors, metastatic colorectal cancer, and platinum-resistant ovarian cancer. Additionally, OncoMed is developing Etigilimab, an anti-TIGIT monoclonal antibody that is currently in clinical trials for advanced or metastatic solid tumors. The company aims to provide new treatment alternatives by leveraging its understanding of cancer stem cells, which are critical to tumor initiation. OncoMed has established strategic alliances with leading pharmaceutical companies, including Celgene Corporation and Bayer Pharma AG, to facilitate the discovery and development of novel therapeutics. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

Proteolix is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies aimed at targeting protein degradation pathways to treat cancer and autoimmune diseases. The company’s lead product is a highly specific proteasome inhibitor, which represents a novel class of therapeutics being evaluated for safety and efficacy in multiple myeloma and other malignancies. In addition to this, Proteolix is developing a diverse pipeline of proteasome inhibitors, including both an oral formulation and a selective immunoproteasome inhibitor. These advancements aim to provide healthcare professionals with effective treatments for various hematologic cancers, thereby improving patient outcomes.

Meritage Pharma, Inc. is a pharmaceutical company based in San Diego, California, specializing in the development of prescription products aimed at treating gastrointestinal and atopic diseases. Founded in 2008, the company focuses on innovative therapies for conditions such as eosinophilic esophagitis, an allergic inflammation of the esophagus. Its lead product candidate is an oral formulation of budesonide, a glucocorticoid steroid known for its effectiveness in managing allergic reactions and inflammation. Additionally, Meritage Pharma offers budesonide as an active pharmaceutical ingredient for various conditions, including pediatric asthma, allergic rhinitis, and Crohn’s disease, thereby addressing a range of health issues associated with allergic inflammation.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

Leptos Biomedical is a company that specializes in developing innovative neuromodulation therapy solutions for chronic obesity. Founded in 2002 and headquartered in Fridley, Minnesota, the company has created a treatment that operates through the electrical activation of a specific nerve within the autonomic nervous system, utilizing a device similar to a pacemaker. This proprietary approach aims to address the complexities of obesity by targeting the underlying neurological factors contributing to the condition.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Evoke Pharma, Inc. is a specialty pharmaceutical company headquartered in Solana Beach, California, dedicated to developing and commercializing treatments for gastrointestinal disorders. Founded in 2007, the company primarily focuses on addressing significant unmet medical needs within the gastroenterology field. Its lead product candidate, Gimoti, is an investigational metoclopramide nasal spray formulated to provide systemic delivery through the nasal mucosa. Gimoti is designed to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women and has completed Phase III clinical trials. Evoke Pharma aims to enhance patient care by developing improved versions of existing therapies and leveraging partnerships with clinical and regulatory experts to advance its product development efforts.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Pharmix is a trading company that provides export solutions for food supplements and various pharmaceutical products.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on discovering and developing innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody designed to target Delta-like ligand 4 and vascular endothelial growth factor, which has undergone clinical trials for advanced solid tumors, metastatic colorectal cancer, and platinum-resistant ovarian cancer. Additionally, OncoMed is developing Etigilimab, an anti-TIGIT monoclonal antibody that is currently in clinical trials for advanced or metastatic solid tumors. The company aims to provide new treatment alternatives by leveraging its understanding of cancer stem cells, which are critical to tumor initiation. OncoMed has established strategic alliances with leading pharmaceutical companies, including Celgene Corporation and Bayer Pharma AG, to facilitate the discovery and development of novel therapeutics. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Xtent is a development stage medical device company specializing in the creation and commercialization of innovative customizable drug-eluting stent systems for the treatment of coronary artery disease (CAD). The company’s stent systems allow physicians to tailor both the length and diameter of the stent directly at the site of the diseased artery, a process known as in-situ customization. This approach aims to enhance the effectiveness of treatment for patients suffering from CAD by providing a more precise fit for individual anatomical needs.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Aria Biosystems is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Aria utilizes proprietary bio-layer interferometry (BLI) that enables self-calibration and measurement of molecular interactions using simple-to-use and inexpensive instrumentation. The entire analysis can be completed within minutes and does not require labeling of either probe or target. Aria's analytical capabilities provide greater value in applications where existing methods such as HPLC, ELISA and surface plasmon resonance (SPR) have limitations in throughput, performance and cost.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.